| Member | Definition | Role |
|---|
| 2-bromoergocryptine mesylate | | bromocriptine methanesulfonate |
| almitrine dimesylate | The dimethanesulfonate salt of almitrine. | almitrine dimesylate |
| camostat mesylate | A methanesulfonate (mesylate) salt prepared from equimolar amounts of camostat and methanesulfonic acid. It is a serine protease inhibitor approved and marketed in Japan in 1985 for the alleviation of acute symptoms associated with chronic pancreatitis. In 1994, it was approved for the treatment of postoperative reflux esophagitis. | camostat mesylate |
| delavirdine mesylate | The monomethanesulfonic acid salt of delavirdine, a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection. | delavirdine mesylate |
| desferrioxamine b mesylate | A methanesulfonate salt obtained by reaction of desferrioxamine B with one molar equivalent of methanesulfonic acid. It is an iron-chelating medicine used to remove excess iron from the body. It binds to iron in the blood, which is then passed out in the urine. | desferrioxamine B mesylate |
| dihydroergocristine monomesylate | The methanesulfonic acid salt of dihydroergocristine. It has been used as the for the symptomatic treatment of mental deterioration associated with cerebrovascular insufficiency and in peripheral vascular disease. It is also a component of ergoloid mesylate (codergocrine mesilate), a mixture of ergot alkaloid derivatives that is used as a vasodilator and has shown mild benefits in the treatment of vascular dementia. | dihydroergocristine mesylate |
| dihydroergotamine mesylate | The methanesulfonic acid salt of dihydroergotamine, a semisynthetic ergot alkaloid with weaker oxytocic and vasoconstrictor properties than ergotamine. Both the mesylate and the tartrate salts are used for the treatment of migraine and orthostatic hypotension. | dihydroergotamine mesylate |
| doxazosin mesylate | | doxazosin mesylate |
| eprosartan mesylate dihydrate | | eprosartan methanesulfonate |
| gabexate methanesulfonate | | gabexate methanesulfonate |
| gemifloxacin mesylate | The mesylate salt of gemifloxacin. | gemifloxacin mesylate |
| hycanthone methanesulfonate | A methanesulfonate salt resulting from the reaction of equimolar amounts of hycanthone and methanesulfonic acid. It was formerly used as a schistosomicide for individual or mass treatement of infection with Schistosoma haematobium and S. mansoni, but due to its toxicity and concern about possible carcinogenicity, it has been replaced by other drugs such as praziquantel. | hycanthone mesylate |
| imatinib mesylate | A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours. | imatinib methanesulfonate |
| nelfinavir mesylate | A methanesulfonate (mesylate) salt prepared from equimolar amounts of nelfinavir and methanesulfonic acid. It is used for treatment of HIV and also exhibits some anticancer properties. | nelfinavir mesylate |
| pefloxacin mesylate | | pefloxacin mesylate |
| pergolide mesylate | A methanesulfonate salt obtained from pergolide by mixing eqimolar amount of pergolide and methanesulfonic acid. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction. | pergolide mesylate |
| tricaine | A methanesulfonate salt obtained by reaction of tricaine with one molar equivalent of methanesulfonic acid. Used as an anaesthetic for fish. | tricaine methanesulfonate |